Invus Global Management, LLC - 02 Feb 2026 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Signature
See Exhibit 99.1
Issuer symbol
LXRX
Transactions as of
02 Feb 2026
Net transactions value
+$54,984,433
Form type
4
Filing time
04 Feb 2026, 16:25:05 UTC
Previous filing
06 Feb 2026

Reporting Owners (9)

Name Relationship Address Signature Signature date CIK
Invus Global Management, LLC Director, 10%+ Owner 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK See Exhibit 99.1 04 Feb 2026 0002005369
Siren, L.L.C. Director, 10%+ Owner C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE 30TH FLOOR, NEW YORK See Exhibit 99.1 04 Feb 2026 0002005245
DEBBANE RAYMOND Director C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE 30TH FLOOR, NEW YORK See Exhibit 99.1 04 Feb 2026 0001053890
Artal Participations S.a r.l. Director, 10%+ Owner VALLEY PARK 44, RUE DE LA VALLEE, LUXEMBOURG, LUXEMBOURG See Exhibit 99.1 04 Feb 2026 0002048403
Artal International S.C.A. Director, 10%+ Owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG, LUXEMBOURG See Exhibit 99.1 04 Feb 2026 0001218180
Artal International Management S.A. Director, 10%+ Owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG, LUXEMBOURG See Exhibit 99.1 04 Feb 2026 0001522131
Artal Group S.A. Director, 10%+ Owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG, LUXEMBOURG See Exhibit 99.1 04 Feb 2026 0001053906
Westend S.A. Director, 10%+ Owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG, LUXEMBOURG See Exhibit 99.1 04 Feb 2026 0001283968
Stichting Administratiekantoor Westend Director, 10%+ Owner H.J.E. WENCKEBACHWEG 252, AMSTERDAM, NETHERLANDS See Exhibit 99.1 04 Feb 2026 0001460840

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXRX Common Stock Award $24,120,000 +18,553,846 +14% $1.30 154,734,327 02 Feb 2026 See Footnotes F1, F4, F9, F15
transaction LXRX Common Stock Award $5,000,000 +3,846,154 +109% $1.30 7,362,368 02 Feb 2026 See Footnotes F1, F5, F10, F15
transaction LXRX Common Stock Purchase $2,000,001 +1,538,462 $1.30 1,538,462 02 Feb 2026 See Footnotes F2, F6, F11, F15
transaction LXRX Series B Convertible Preferred Stock Award $23,864,433 +367,145 $65.00 367,145 02 Feb 2026 See Footnotes F3, F4, F9, F15
holding LXRX Common Stock 35,402,689 02 Feb 2026 See Footnotes F7, F12, F15
holding LXRX Common Stock 5,451,204 02 Feb 2026 See Footnotes F8, F13, F15
holding LXRX Common Stock 1,385,689 02 Feb 2026 See Footnotes F14, F15
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On January 29, 2026, Artal Participations S.a r.l. entered into a purchase agreement with the Issuer pursuant to which Artal Participations S.a r.l. agreed to purchase 22,400,000 shares of common stock par value $0.001 per share (the "Common Stock") of the Issuer at a price of $1.30 per share (the "Purchase Price"). On January 30, 2026, Artal Participations S.a r.l. assigned its right to purchase from the Issuer 3,846,154 shares of Issuer Common Stock to Invus Public Equities, L.P., and Invus Public Equities, L.P. agreed to purchase directly from the Issuer 3,846,154 shares of Issuer Common Stock at the Purchase Price. The purchase closed on February 2, 2026.
F2 On February 2, 2026, Avicenna Life Sci Master Fund LP purchased 1,538,462 shares of Common Stock as part of the Issuer's underwritten public offering.
F3 On January 29, 2026, Artal Participations S.a r.l. entered into a preferred stock purchase agreement (the "Preferred Purchase Agreement") with the Issuer pursuant to which Artal Participations S.a r.l. agreed to purchase 367,145.12 shares of Series B Convertible Preferred Stock, par value $0.01 per share (the "Preferred Stock") of the Issuer at a price of $65.00 per share. The Preferred Purchase Agreement also provides Artal Participations S.a r.l. the right to purchase from the Issuer, up to an additional 94,854.88 shares of Preferred Stock at a price per share of $65.00. Each share of Preferred Stock will automatically convert into 50 shares of the Issuer's Common Stock upon receipt of shareholder approval and the satisfaction of certain other conditions; however, absent the satisfaction of such conditions, the shares are not convertible. The purchase closed on February 2, 2026.
F4 These securities are directly held by Artal Participations S.a r.l.
F5 These securities are directly held by Invus Public Equities, L.P.
F6 These securities are directly held by Avicenna Life Sci Master Fund LP
F7 These securities are directly held by Invus, L.P.
F8 These securities are directly held by Invus US Partners LLC
F9 The sole shareholder of Artal Participations S.a r.l. is Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting.
F10 The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. The managing member of Invus Public Equities Advisors, LLC is Invus Global Management, LLC. The managing member of Invus Global Management, LLC is Siren, L.L.C. The managing member of Siren, L.L.C. is Mr. Raymond Debbane.
F11 The general partner of Avicenna Life Sci Master Fund LP is Avicenna Life Sci Master GP LLC. The managing member of Avicenna Life Sci Master GP LLC is Ulys, L.L.C. The managing member of Ulys, L.L.C. is Mr. Raymond Debbane.
F12 The general partner of Invus, L.P. is Invus Advisors, L.L.C. The managing member of Invus Advisors, L.L.C. is Invus Global Management, LLC. The managing member of Invus Global Management, LLC. is Siren, L.L.C. The managing member of Siren, L.L.C. is Mr. Raymond Debbane.
F13 The managing member of Invus US Partners LLC is Ulys, L.L.C. The managing member of Ulys, L.L.C. is Mr. Raymond Debbane.
F14 These securities are directly held by Mr. Raymond Debbane.
F15 Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Remarks:

For purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization of the Issuer by virtue of Invus, L.P.'s right to designate certain members of the Issuer's board of directors pursuant to a stockholders' agreement between the Issuer and Invus, L.P.